Literature DB >> 9435768

High interindividual variability of methadone enantiomer blood levels to dose ratios.

C B Eap, G Bertschy, P Baumann, T Finkbeiner, M Gastpar, N Scherbaum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9435768     DOI： 10.1001/archpsyc.55.1.89

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN： 0003-990X


× No keyword cloud information.
  11 in total

1.  Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.

Authors:  James Rosado; Sharon L Walsh; George E Bigelow; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2007-05-22       Impact factor: 4.492

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.

Authors:  Kristin Moksnes; Stein Kaasa; Ørnulf Paulsen; Jan Henrik Rosland; Olav Spigset; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2012-02-29       Impact factor: 2.953

4.  Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects.

Authors:  Julia Hanna; David J R Foster; Amy Salter; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

5.  Estimated infant exposure to enantiomer-specific methadone levels in breastmilk.

Authors:  Debra L Bogen; James M Perel; Joseph C Helsel; Barbara H Hanusa; Matthew Thompson; Katherine L Wisner
Journal:  Breastfeed Med       Date:  2011-02-24       Impact factor: 1.817

6.  A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.

Authors:  D W Boulton; P Arnaud; C L DeVane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

7.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

8.  Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.

Authors:  D L Bogen; J M Perel; J C Helsel; B H Hanusa; M Romkes; T Nukui; C R Friedman; K L Wisner
Journal:  Psychopharmacology (Berl)       Date:  2012-08-25       Impact factor: 4.530

9.  Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study.

Authors:  Zainab Samaan; Monica Bawor; Brittany B Dennis; Carolyn Plater; Michael Varenbut; Jeffrey Daiter; Andrew Worster; David C Marsh; Charlie Tan; Dipika Desai; Lehana Thabane; Guillaume Pare
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-19       Impact factor: 2.570

10.  The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.

Authors:  Brittany Burns Dennis; Leen Naji; Monica Bawor; Ashley Bonner; Michael Varenbut; Jeff Daiter; Carolyn Plater; Guillaume Pare; David C Marsh; Andrew Worster; Dipika Desai; Zainab Samaan; Lehana Thabane
Journal:  Syst Rev       Date:  2014-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.